As reported in The New England Journal of Medicine by Ghassan K. Abou‑Alfa, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the second interim analysis of the phase III CELESTIAL trial has shown a significant improvement in overall and progression-free survival with cabozantinib (Cometriq) vs placebo in patients with sorafenib (Nexavar)-treated advanced hepatocellular carcinoma.1 Cabozantinib is an inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, MET, and AXL kinases, which are associated with progressive disease and sorafenib resistance.
In the double-blind trial, 773 patients from 95 sites in 19 countries were randomly assigned 2:1 between September 2013 and September 2017 to receive cabozantinib (60 mg once daily) or placebo. At data cutoff for the second interim analysis of overall survival in June 2017, 707 patients had been randomly assigned to receive cabozantinib (n = 470) or placebo (n = 237). Eligible patients had received previous treatment with sorafenib, had disease progression after at least one systemic treatment for hepatocellular carcinoma, and could have received up to two previous systemic regimens for advanced disease. Patients had to have Child-Pugh class A liver function. Randomization was stratified by etiologic factor (hepatitis B virus [HBV] with or without hepatitis C virus [HCV], HCV without HBV, or other); geographic region (Asia or other); and evidence of extrahepatic spread of disease, macrovascular invasion, or both (yes or no). The primary endpoint was overall survival in the intent-to-treat population.
For the cabozantinib vs placebo groups: the median age was 64 years in both; 81% vs 85% were male; 25% vs 25% were from Asia, 49% vs 46% were from Europe, and 23% vs 25% were from the United States and Canada; Eastern Cooperative Oncology Group performance status was 0 for 52% vs 55% and 1 for 48% vs 45%; etiologic factors included HBV in 38% vs 38%, HCV in 24% vs 23%, and both in 2% vs 2%; and extrahepatic spread of disease (79% vs 77%), macrovascular invasion (27% vs 34%), or both were present in 85% vs 84%. All patients had received sorafenib, and 27% had received two previous systemic anticancer regimens for advanced disease.
The second interim analysis occurred after 484 deaths (78% of the 621 deaths planned for the prespecified final analysis). As of data cutoff for the interim analysis, 26% of patients in the cabozantinib group and 33% in the placebo group had received subsequent systemic or local anticancer therapy excluding radiotherapy. A total of 16% of the cabozantinib group and 11% of the placebo group were still receiving study treatment.
Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo.— Ghassan K. Abou‑Alfa, MD, and colleagues
Tweet this quote
Median overall survival was 10.2 months (95% confidence interval [CI] = 9.1–12.0 months) in the cabozantinib group vs 8.0 months (95% CI = 6.8–9.4 months) in the placebo group (stratified hazard ratio [HR] = 0.76, P = .005). Kaplan-Meier estimates of overall survival were 72% vs 61% at 6 months, 46% vs 34% at 12 months, 32% vs 18% at 18 months, and 18% vs 13% at 24 months. In a subgroup analysis, the median overall survival was 11.3 vs 7.2 months among patients whose only prior systemic therapy was sorafenib (HR = 0.70, 95% CI = 0.55–0.88), 8.6 vs 8.6 months among patients receiving two prior systemic therapies (HR = 0.90, 95% CI = 0.63–1.29), 10.9 vs 10.2 months for patients from Asia (HR = 1.01, 95% CI = 0.68–1.48), and 10.2 vs 7.8 months for patients from other regions (HR = 0.71, 95% CI = 0.57–0.88).
The median progression-free survival was 5.2 months with cabozantinib and 1.9 months with placebo (HR = 0.44, P < .001), including 5.5 vs 1.9 months among patients who had received only sorafenib (HR = 0.40, 95% CI = 0.32–0.50) and 3.7 vs 1.9 months among those receiving two prior therapies (HR = 0.58, 95% CI = 0.41–0.83). Objective response rates were 4% vs < 1% (P = .009).
Grade 3 or 4 adverse events occurred in 68% of patients in the cabozantinib group vs 36% in the placebo group, with the most common being palmar-plantar erythrodysesthesia (17% vs 0%), hypertension (16% vs 2%), increased aspartate transaminase (AST) level (12% vs 7%), fatigue (10% vs 4%), and diarrhea (10% vs 2%). Serious adverse events were reported in 50% of the cabozantinib group vs 37% of the placebo group. Adverse events leading to death that were considered related to study treatment occurred in six patients in the cabozantinib group (one event each of hepatic failure, bronchoesophageal fistula, portal vein thrombosis, upper gastrointestinal hemorrhage, pulmonary embolism, and hepatorenal syndrome) and in one patient in the placebo group (hepatic failure).
The investigators concluded: “Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. The rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group.” ■
DISCLOSURE: The study was funded by Exelixis. For full disclosures of the study authors, visit www.nejm.org.
1. Abou‑Alfa GK, Meyer T, Cheng AL, et al: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379:54-63, 2018.
Amit Mahipal, MBBS
Lewis R. Roberts, MB, ChB, PhD
As reported in The New England Journal of Medicine by Ghassan K. Abou-Alfa, MD, and colleagues, and reviewed in this issue of The ASCO Post, the phase III CELESTIAL trial has demonstrated that cabozantinib (Cabometyx) improved the...!-->!-->!-->!-->